UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/517,939	07/27/2005	Brian Steer	564462007901	6876

45975 7590 10/04/2007

VERENIUM C/O MOFO S.D.
12531 HIGH BLUFF DRIVE
SUITE 100
SAN DIEGO, CA 92130-2040

EXAMINER	
PROUTY, REBECCA E	
ART UNIT	**PAPER NUMBER**
1652	

MAIL DATE	DELIVERY MODE
10/04/2007	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Office Action Summary	Application No.	Applicant(s)	
	10/517,939	STEER ET AL.	
	Examiner	Art Unit	
	Rebecca E. Prouty	1652	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

1)☐ Responsive to communication(s) filed on _____.

2a)☐ This action is **FINAL**. 2b)☒ This action is non-final.

3)☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

4)☒ Claim(s) *216-240* is/are pending in the application.

4a) Of the above claim(s) _____ is/are withdrawn from consideration.

5)☐ Claim(s) _____ is/are allowed.

6)☐ Claim(s) _____ is/are rejected.

7)☐ Claim(s) _____ is/are objected to.

8)☒ Claim(s) *216-240* are subject to restriction and/or election requirement.

Application Papers

9)☐ The specification is objected to by the Examiner.

10)☐ The drawing(s) filed on _____ is/are: a)☐ accepted or b)☐ objected to by the Examiner.

Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).

Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).

11)☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

12)☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).

a)☐ All b)☐ Some * c)☐ None of:

1.☐ Certified copies of the priority documents have been received.

2.☐ Certified copies of the priority documents have been received in Application No. _____.

3.☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

1) ☐ Notice of References Cited (PTO-892)
2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
3) ☐ Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date _____.
4) ☐ Interview Summary (PTO-413) Paper No(s)/Mail Date. _____ .
5) ☐ Notice of Informal Patent Application
6) ☐ Other: _____.

Claims 1-215 have been canceled. Claims 216-240 are at issue and are present for examination.

Restriction to one of the following inventions is required under 35 U.S.C. 121:

I. Claims 216 and 217, drawn to methods of making a composition comprising a xylanase, classified in class 435, subclass 200.

II. Claims 218-220, 235, and 238, drawn to a xylanase and compositions thereof, classified in class 435, subclass 200.

III. Claims 221-222, drawn to methods of using a xylanase to hydrolyze xylan, classified in class 435, subclass 99.

IV. Claims 223-228, drawn to methods of reducing the lignin content of wood using a xylanase, classified in class 435, subclass 278.

V. Claims 227-234 and 239-240, drawn to methods of bleaching or deinking wood or paper products using a xylanase, classified in class 435, subclass 278.

VI. Claims 236-237 drawn to methods of using a xylanase to produce ethanol, classified in class 435, subclass 161.

For each of inventions I-VI above, restriction to one of the following is also required under 35 USC 121. Therefore, election is required of one of inventions I-VI and one of inventions (A)-(GH).

(A). protein of SEQ ID No: 2 or a nucleic acid encoding SEQ ID No: 2.

(B). protein of SEQ ID No: 4 or a nucleic acid encoding SEQ ID No: 4.

(C). protein of SEQ ID No: 6 or a nucleic acid encoding SEQ ID No: 6.

(D). protein of SEQ ID No: 8 or a nucleic acid encoding SEQ ID No: 8.

(E). protein of SEQ ID No: 10 or a nucleic acid encoding SEQ ID No: 10.

(F). protein of SEQ ID No: 12 or a nucleic acid encoding SEQ ID No: 12.

(G). protein of SEQ ID No: 14 or a nucleic acid encoding SEQ ID No: 14.

(H). protein of SEQ ID No: 16 or a nucleic acid encoding SEQ ID No: 16.

(I). protein of SEQ ID No: 18 or a nucleic acid encoding SEQ ID No: 18.

(J). protein of SEQ ID No: 20 or a nucleic acid encoding SEQ ID No: 20.

(K). protein of SEQ ID No: 22 or a nucleic acid encoding SEQ ID No: 22.

(L). protein of SEQ ID No: 24 or a nucleic acid encoding SEQ ID No: 24.

(M). protein of SEQ ID No: 26 or a nucleic acid encoding SEQ ID No: 26.

(N). protein of SEQ ID No: 28 or a nucleic acid encoding SEQ ID No: 28.

(O). protein of SEQ ID No: 30 or a nucleic acid encoding SEQ ID No: 30.

(P). protein of SEQ ID No: 32 or a nucleic acid encoding SEQ ID No: 32.

(Q). protein of SEQ ID No: 34 or a nucleic acid encoding SEQ ID No: 34.

(R). protein of SEQ ID No: 36 or a nucleic acid encoding SEQ ID No: 36.

(S). protein of SEQ ID No: 38 or a nucleic acid encoding SEQ ID No: 38.

(T). protein of SEQ ID No: 40 or a nucleic acid encoding SEQ ID No: 40.

(U). protein of SEQ ID No: 42 or a nucleic acid encoding SEQ ID No: 42.

(V). protein of SEQ ID No: 44 or a nucleic acid encoding SEQ ID No: 44.

(W). protein of SEQ ID No: 46 or a nucleic acid encoding SEQ ID No: 46.

(X). protein of SEQ ID No: 48 or a nucleic acid encoding SEQ ID No: 48.

(Y). protein of SEQ ID No: 50 or a nucleic acid encoding SEQ ID No: 50.

(Z). protein of SEQ ID No: 52 or a nucleic acid encoding SEQ ID No: 52.

(AA). protein of SEQ ID No: 54 or a nucleic acid encoding SEQ ID No: 54.

(AB). protein of SEQ ID No: 56 or a nucleic acid encoding SEQ ID No: 56.

(AC). protein of SEQ ID No: 58 or a nucleic acid encoding SEQ ID No: 58.

(AD). protein of SEQ ID No: 60 or a nucleic acid encoding SEQ ID No: 60.

(AE). protein of SEQ ID No: 62 or a nucleic acid encoding SEQ ID No: 62.

(AF). protein of SEQ ID No: 64 or a nucleic acid encoding SEQ ID No: 64.

(AG). protein of SEQ ID No: 66 or a nucleic acid encoding SEQ ID No: 66.

(AH). protein of SEQ ID No: 68 or a nucleic acid encoding SEQ ID No: 68.

(AI). protein of SEQ ID No: 70 or a nucleic acid encoding SEQ ID No: 70.

(AJ). protein of SEQ ID No: 72 or a nucleic acid encoding SEQ ID No: 72.

(AK). protein of SEQ ID No: 74 or a nucleic acid encoding SEQ ID No: 74.

(AL). protein of SEQ ID No: 76 or a nucleic acid encoding SEQ ID No: 76.

(AM). protein of SEQ ID No: 78 or a nucleic acid encoding SEQ ID No: 78.

(AN). protein of SEQ ID No: 80 or a nucleic acid encoding SEQ ID No: 80.

(AO). protein of SEQ ID No: 82 or a nucleic acid encoding SEQ ID No: 82.

(AP). protein of SEQ ID No: 84 or a nucleic acid encoding SEQ ID No: 84.

(AQ). protein of SEQ ID No: 86 or a nucleic acid encoding SEQ ID No: 86.

(AR). protein of SEQ ID No: 88 or a nucleic acid encoding SEQ ID No: 88.

(AS). protein of SEQ ID No: 90 or a nucleic acid encoding SEQ ID No: 90.

(AT). protein of SEQ ID No: 92 or a nucleic acid encoding SEQ ID No: 92.

(AU). protein of SEQ ID No: 94 or a nucleic acid encoding SEQ ID No: 94.

(AV). protein of SEQ ID No: 96 or a nucleic acid encoding SEQ ID No: 96.

(AW). protein of SEQ ID No: 98 or a nucleic acid encoding SEQ ID No: 98.

(AX). protein of SEQ ID No: 100 or a nucleic acid encoding SEQ ID No: 100.

(AY). protein of SEQ ID No: 102 or a nucleic acid encoding SEQ ID No: 102.

(AZ). protein of SEQ ID No: 104 or a nucleic acid encoding SEQ ID No: 104.

(BA). protein of SEQ ID No: 106 or a nucleic acid encoding SEQ ID No: 106.

(BB). protein of SEQ ID No: 108 or a nucleic acid encoding SEQ ID No: 108.

(BC). protein of SEQ ID No: 110 or a nucleic acid encoding SEQ ID No: 110.

(BD). protein of SEQ ID No: 112 or a nucleic acid encoding SEQ ID No: 112.

(AE). protein of SEQ ID No: 114 or a nucleic acid encoding SEQ ID No: 114.

(BF). protein of SEQ ID No: 116 or a nucleic acid encoding SEQ ID No: 116.

(BG). protein of SEQ ID No: 118 or a nucleic acid encoding SEQ ID No: 118.

(BH). protein of SEQ ID No: 120 or a nucleic acid encoding SEQ ID No: 120.

(BI). protein of SEQ ID No: 122 or a nucleic acid encoding SEQ ID No: 122.

(BJ). protein of SEQ ID No: 124 or a nucleic acid encoding SEQ ID No: 124.

(BK). protein of SEQ ID No: 126 or a nucleic acid encoding SEQ ID No: 126.

(BL). protein of SEQ ID No: 128 or a nucleic acid encoding SEQ ID No: 128.

(BM). protein of SEQ ID No: 130 or a nucleic acid encoding SEQ ID No: 130.

(BN). protein of SEQ ID No: 132 or a nucleic acid encoding SEQ ID No: 132.

(BO). protein of SEQ ID No: 134 or a nucleic acid encoding SEQ ID No: 134.

(BP). protein of SEQ ID No: 136 or a nucleic acid encoding SEQ ID No: 136.

(BQ). protein of SEQ ID No: 138 or a nucleic acid encoding SEQ ID No: 138.

(BR). protein of SEQ ID No: 140 or a nucleic acid encoding SEQ ID No: 140.

(BS). protein of SEQ ID No: 142 or a nucleic acid encoding SEQ ID No: 142.

(BT). protein of SEQ ID No: 144 or a nucleic acid encoding SEQ ID No: 144.

(BU). protein of SEQ ID No: 146 or a nucleic acid encoding SEQ ID No: 146.

(BV). protein of SEQ ID No: 148 or a nucleic acid encoding SEQ ID No: 148.

(BW). protein of SEQ ID No: 150 or a nucleic acid encoding SEQ ID No: 150.

(BX). protein of SEQ ID No: 152 or a nucleic acid encoding SEQ ID No: 152.

(BY). protein of SEQ ID No: 154 or a nucleic acid encoding SEQ ID No: 154.

(BZ). protein of SEQ ID No: 156 or a nucleic acid encoding SEQ ID No: 156.

(CA). protein of SEQ ID No: 158 or a nucleic acid encoding SEQ ID No: 158.

(CB). protein of SEQ ID No: 160 or a nucleic acid encoding SEQ ID No: 160.

(CC). protein of SEQ ID No: 162 or a nucleic acid encoding SEQ ID No: 162.

(CD). protein of SEQ ID No: 164 or a nucleic acid encoding SEQ ID No: 164.

(CE). protein of SEQ ID No: 166 or a nucleic acid encoding SEQ ID No: 166.

(CF). protein of SEQ ID No: 168 or a nucleic acid encoding SEQ ID No: 168.

(CG). protein of SEQ ID No: 170 or a nucleic acid encoding SEQ ID No: 170.

(CH). protein of SEQ ID No: 172 or a nucleic acid encoding SEQ ID No: 172.

(CI). protein of SEQ ID No: 174 or a nucleic acid encoding SEQ ID No: 174.

(CJ). protein of SEQ ID No: 176 or a nucleic acid encoding SEQ ID No: 176.

(CK). protein of SEQ ID No: 178 or a nucleic acid encoding SEQ ID No: 178.

(CL). protein of SEQ ID No: 180 or a nucleic acid encoding SEQ ID No: 180.

(CM). protein of SEQ ID No: 182 or a nucleic acid encoding SEQ ID No: 182.

(CN). protein of SEQ ID No: 184 or a nucleic acid encoding SEQ ID No: 184.

(CO). protein of SEQ ID No: 186 or a nucleic acid encoding SEQ ID No: 186.

(CP). protein of SEQ ID No: 188 or a nucleic acid encoding SEQ ID No: 188.

(CQ). protein of SEQ ID No: 190 or a nucleic acid encoding SEQ ID No: 190.

(CR). protein of SEQ ID No: 192 or a nucleic acid encoding SEQ ID No: 192.

(CS). protein of SEQ ID No: 194 or a nucleic acid encoding SEQ ID No: 194.

(CT). protein of SEQ ID No: 196 or a nucleic acid encoding SEQ ID No: 196.

(CU). protein of SEQ ID No: 198 or a nucleic acid encoding SEQ ID No: 198.

(CV). protein of SEQ ID No: 200 or a nucleic acid encoding SEQ ID No: 200.

(CW). protein of SEQ ID No: 202 or a nucleic acid encoding SEQ ID No: 202.

(CX). protein of SEQ ID No: 204 or a nucleic acid encoding SEQ ID No: 204.

(CY). protein of SEQ ID No: 206 or a nucleic acid encoding SEQ ID No: 206.

(CZ). protein of SEQ ID No: 208 or a nucleic acid encoding SEQ ID No: 208.

(DA). protein of SEQ ID No: 210 or a nucleic acid encoding SEQ ID No: 210.

(DB). protein of SEQ ID No: 212 or a nucleic acid encoding SEQ ID No: 212.

(DC). protein of SEQ ID No: 214 or a nucleic acid encoding SEQ ID No: 214.

(DD). protein of SEQ ID No: 216 or a nucleic acid encoding SEQ ID No: 216.

(DE). protein of SEQ ID No: 218 or a nucleic acid encoding SEQ ID No: 218.

(DF). protein of SEQ ID No: 220 or a nucleic acid encoding SEQ ID No: 220.

(DG). protein of SEQ ID No: 222 or a nucleic acid encoding SEQ ID No: 222.

(DH). protein of SEQ ID No: 224 or a nucleic acid encoding SEQ ID No: 224.

(DI). protein of SEQ ID No: 226 or a nucleic acid encoding SEQ ID No: 226.

(DJ). protein of SEQ ID No: 228 or a nucleic acid encoding SEQ ID No: 228.

(DK). protein of SEQ ID No: 230 or a nucleic acid encoding SEQ ID No: 230.

(DL). protein of SEQ ID No: 232 or a nucleic acid encoding SEQ ID No: 232.

(DM). protein of SEQ ID No: 234 or a nucleic acid encoding SEQ ID No: 234.

(DN). protein of SEQ ID No: 236 or a nucleic acid encoding SEQ ID No: 236.

(DO). protein of SEQ ID No: 238 or a nucleic acid encoding SEQ ID No: 238.

(DP). protein of SEQ ID No: 240 or a nucleic acid encoding SEQ ID No: 240.

(DQ). protein of SEQ ID No: 242 or a nucleic acid encoding SEQ ID No: 242.

(DR). protein of SEQ ID No: 244 or a nucleic acid encoding SEQ ID No: 244.

(DS). protein of SEQ ID No: 246 or a nucleic acid encoding SEQ ID No: 246.

(DT). protein of SEQ ID No: 248 or a nucleic acid encoding SEQ ID No: 248.

(DU). protein of SEQ ID No: 250 or a nucleic acid encoding SEQ ID No: 250.

(DV). protein of SEQ ID No: 252 or a nucleic acid encoding SEQ ID No: 252.

(DW). protein of SEQ ID No: 254 or a nucleic acid encoding SEQ ID No: 254.

(DX). protein of SEQ ID No: 256 or a nucleic acid encoding SEQ ID No: 256.

(DY). protein of SEQ ID No: 258 or a nucleic acid encoding SEQ ID No: 258.

(DZ). protein of SEQ ID No: 260 or a nucleic acid encoding SEQ ID No: 260.

(EA). protein of SEQ ID No: 262 or a nucleic acid encoding SEQ ID No: 262.

(EB). protein of SEQ ID No: 264 or a nucleic acid encoding SEQ ID No: 264.

(EC). protein of SEQ ID No: 266 or a nucleic acid encoding SEQ ID No: 266.

(ED). protein of SEQ ID No: 268 or a nucleic acid encoding SEQ ID No: 268.

(EE). protein of SEQ ID No: 270 or a nucleic acid encoding SEQ ID No: 270.

(EF). protein of SEQ ID No: 272 or a nucleic acid encoding SEQ ID No: 272.

(EG). protein of SEQ ID No: 274 or a nucleic acid encoding SEQ ID No: 274.

(EH). protein of SEQ ID No: 276 or a nucleic acid encoding SEQ ID No: 276.

(EI). protein of SEQ ID No: 278 or a nucleic acid encoding SEQ ID No: 278.

(EJ). protein of SEQ ID No: 280 or a nucleic acid encoding SEQ ID No: 280.

(EK). protein of SEQ ID No: 282 or a nucleic acid encoding SEQ ID No: 282.

(EL). protein of SEQ ID No: 284 or a nucleic acid encoding SEQ ID No: 284.

(EM). protein of SEQ ID No: 286 or a nucleic acid encoding SEQ ID No: 286.

(EN). protein of SEQ ID No: 288 or a nucleic acid encoding SEQ ID No: 288.

(EO). protein of SEQ ID No: 290 or a nucleic acid encoding SEQ ID No: 290.

(EP). protein of SEQ ID No: 292 or a nucleic acid encoding SEQ ID No: 292.

(EQ). protein of SEQ ID No: 294 or a nucleic acid encoding SEQ ID No: 294.

(ER). protein of SEQ ID No: 296 or a nucleic acid encoding SEQ ID No: 296.

(ES). protein of SEQ ID No: 298 or a nucleic acid encoding SEQ ID No: 298.

(ET). protein of SEQ ID No: 300 or a nucleic acid encoding SEQ ID No: 300.

(EU). protein of SEQ ID No: 302 or a nucleic acid encoding SEQ ID No: 302.

(EV). protein of SEQ ID No: 304 or a nucleic acid encoding SEQ ID No: 304.

(EW). protein of SEQ ID No: 306 or a nucleic acid encoding SEQ ID No: 306.

(EX). protein of SEQ ID No: 308 or a nucleic acid encoding SEQ ID No: 308.

(EY). protein of SEQ ID No: 310 or a nucleic acid encoding SEQ ID No: 310.

(EZ). protein of SEQ ID No: 312 or a nucleic acid encoding SEQ ID No: 312.

(FA). protein of SEQ ID No: 314 or a nucleic acid encoding SEQ ID No: 314.

(FB). protein of SEQ ID No: 316 or a nucleic acid encoding SEQ ID No: 316.

(FC). protein of SEQ ID No: 318 or a nucleic acid encoding SEQ ID No: 318.

(FD). protein of SEQ ID No: 320 or a nucleic acid encoding SEQ ID No: 320.

(FE). protein of SEQ ID No: 322 or a nucleic acid encoding SEQ ID No: 322.

(FF). protein of SEQ ID No: 324 or a nucleic acid encoding SEQ ID No: 324.

(FG). protein of SEQ ID No: 326 or a nucleic acid encoding SEQ ID No: 326.

(FH). protein of SEQ ID No: 328 or a nucleic acid encoding SEQ ID No: 328.

(FI). protein of SEQ ID No: 330 or a nucleic acid encoding SEQ ID No: 330.

(FJ). protein of SEQ ID No: 332 or a nucleic acid encoding SEQ ID No: 332.

(FK). protein of SEQ ID No: 334 or a nucleic acid encoding SEQ ID No: 334.

(FL). protein of SEQ ID No: 336 or a nucleic acid encoding SEQ ID No: 336.

(FM). protein of SEQ ID No: 338 or a nucleic acid encoding SEQ ID No: 338.

(FN). protein of SEQ ID No: 340 or a nucleic acid encoding SEQ ID No: 340.

(FO). protein of SEQ ID No: 342 or a nucleic acid encoding SEQ ID No: 342.

(FP). protein of SEQ ID No: 344 or a nucleic acid encoding SEQ ID No: 344.

(FQ). protein of SEQ ID No: 346 or a nucleic acid encoding SEQ ID No: 346.

(FR). protein of SEQ ID No: 348 or a nucleic acid encoding SEQ ID No: 348.

(FS). protein of SEQ ID No: 350 or a nucleic acid encoding SEQ ID No: 350.

(FT). protein of SEQ ID No: 352 or a nucleic acid encoding SEQ ID No: 352.

(FU). protein of SEQ ID No: 354 or a nucleic acid encoding SEQ ID No: 354.

(FV). protein of SEQ ID No: 356 or a nucleic acid encoding SEQ ID No: 356.

(FW). protein of SEQ ID No: 358 or a nucleic acid encoding SEQ ID No: 358.

(FX). protein of SEQ ID No: 360 or a nucleic acid encoding SEQ ID No: 360.

(FY). protein of SEQ ID No: 362 or a nucleic acid encoding SEQ ID No: 362.

(FZ). protein of SEQ ID No: 364 or a nucleic acid encoding SEQ ID No: 364.

(GA). protein of SEQ ID No: 366 or a nucleic acid encoding SEQ ID No: 366.

(GB). protein of SEQ ID No: 368 or a nucleic acid encoding SEQ ID No: 368.

(GC). protein of SEQ ID No: 370 or a nucleic acid encoding SEQ ID No: 370.

(GD). protein of SEQ ID No: 372 or a nucleic acid encoding SEQ ID No: 372.

(GE). protein of SEQ ID No: 374 or a nucleic acid encoding SEQ ID No: 374.

(GF). protein of SEQ ID No: 376 or a nucleic acid encoding SEQ ID No: 376.

(GG). protein of SEQ ID No: 378 or a nucleic acid encoding SEQ ID No: 378.

(GH). protein of SEQ ID No: 380 or a nucleic acid encoding SEQ ID No: 380.

Furthermore, if applicants elect group II, above, restriction to one of the following is also required under 35 USC 121.

(1) wood/pulp/paper compositions (Claim 235)

(2) ethanol compositions (Claim 238)

The inventions are distinct, each from the other because of the following reasons:

Inventions I and II are related as process of making and product made. The inventions are distinct if either or both of the following can be shown: (1) that the process as claimed can be used to make another and materially different product or (2) that the product as claimed can be made by another and materially different process (MPEP § 806.05(f)). In the instant

case the composition of groups II can be made by recombinant expression and secretion of the xylanase into a media and isolation of the media.

Inventions II and III-VI are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (M.P.E.P. § 806.05(h)). In the instant case the protein of Group II can be used to induce antibodies.

The methods of Groups I and III-VI are independent as they comprise different steps, utilize different products and produce different results.

The proteins and nucleic acids of Groups (A)-(GH) are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case the different inventions, represent structurally different polypeptides or polynucleotides. Therefore, where structural identity is required, such as for antibody binding,

hybridization or expression, the different sequences have different effects.

The compositions of Groups (1)-(2) are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case the different inventions, represent compositions which are not used together and each have distinct purposes and effects.

Restriction for examination purposes as indicated is proper because all these inventions listed in this action are independent or distinct for the reasons given above and there would be a serious search and examination burden if restriction were not required because one or more of the following reasons apply:

(a) the inventions have acquired a separate status in the art in view of their different classification;

(b) the inventions have acquired a separate status in the art due to their recognized divergent subject matter;

(c) the inventions require a different field of search (for example, searching different classes/subclasses or electronic resources, or employing different search queries);

(d) the prior art applicable to one invention would not likely be applicable to another invention;

(e) the inventions are likely to raise different non-prior art issues under 35 U.S.C. 101 and/or 35 U.S.C. 112, first paragraph.

Applicant is advised that the reply to this requirement to be complete must include (i) an election of a invention to be examined even though the requirement may be traversed (37 CFR 1.143) **and (ii) identification of the claims encompassing the elected invention.**

The election of an invention may be made with or without traverse. To reserve a right to petition, the election must be made with traverse. If the reply does not distinctly and specifically point out supposed errors in the restriction requirement, the election shall be treated as an election without traverse. Traversal must be presented at the time of election in order to be considered timely. Failure to timely traverse the requirement will result in the loss of right to petition under 37 CFR 1.144. If claims are added after the election, applicant must indicate which of these claims are readable on the elected invention.

If claims are added after the election, applicant must indicate which of these claims are readable upon the elected invention.

Should applicant traverse on the ground that the inventions are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the inventions to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a petition under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

The examiner has required restriction between product and process claims. Where applicant elects claims directed to the product, and a product claim is subsequently found allowable, withdrawn process claims that depend from or otherwise include all the limitations of the allowable product claim will be rejoined in accordance with the provisions of MPEP § 821.04. **Process claims that depend from or otherwise include all the limitations of the patentable product** will be entered as a matter of right if the amendment is presented prior to final rejection or allowance, whichever is earlier. Amendments submitted after final rejection are governed by 37 CFR 1.116; amendments submitted after allowance are governed by 37 CFR 1.312.

In the event of rejoinder, the requirement for restriction between the product claims and the rejoined process claims will be withdrawn, and the rejoined process claims will be fully examined for patentability in accordance with 37 CFR 1.104. Thus, to be allowable, the rejoined claims must meet all criteria for patentability including the requirements of 35 U.S.C. 101, 102, 103, and 112. Until an elected product claim is found allowable, an otherwise proper restriction requirement between product claims and process claims may be maintained. Withdrawn process claims that are not commensurate in scope with

an allowed product claim will not be rejoined. See "Guidance on Treatment of Product and Process Claims in light of *In re Ochiai, In re Brouwer* and 35 U.S.C. § 103(b)," 1184 O.G. 86 (March 26, 1996). Additionally, in order to retain the right to rejoinder in accordance with the above policy, Applicant is advised that the process claims should be amended during prosecution either to maintain dependency on the product claims or to otherwise include the limitations of the product claims. **Failure to do so may result in a loss of the right to rejoinder.**

Further, note that the prohibition against double patenting rejections of 35 U.S.C. 121 does not apply where the restriction requirement is withdrawn by the examiner before the patent issues. See MPEP § 804.01.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Rebecca E. Prouty whose telephone number is 571-272-0937. The examiner can normally be reached on Tuesday-Friday from 8 AM to 5 PM. The examiner can also be reached on alternate Mondays

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ponnathapura Achutamurthy, can be reached at (571) 272-0928. The fax phone number for this Group is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on

access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

/Rebecca Prouty/
Primary Examiner
Art Unit 1652